Company intelligence / Profile preview
Elastin Biosciences
London, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
Preclinical in vivo studies showed a 5-fold increase in elastin expression, increased arterial tensile strength, improved metabolic profiles, reduced inflammation, and reversal of key gene expression deficits in rare elastin-deficiency models; IND-enabling studies are ongoing with first-in-human trials targeted for 2025.
- Therapeutic areas
- CardiovascularOtherRare Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Elastin Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Elastin Biosciences.